Polymer-drug conjugates: Recent progress on administration routes

Expert Opinion on Drug Delivery

Volumn 11, Issue 7, 2014, Pages 1075-1086

  Pang, Xin ^a   Yang, Xiaoye ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Intravenous route; Ocular administration; Oral route; Polymer drug conjugates; Pulmonary administration; Routes of administration; Transdermal route

Indexed keywords

CARBOXYMETHYLDEXTRAN; CHITOSAN; CISPLATIN; DENDRIMER; DRUG CARRIER; FLUOCINOLONE ACETONIDE; HYALURONIC ACID; METHYLPREDNISOLONE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NALOXEGOL; POLYAMIDOAMINE; POLYMER; POLYVINYL ALCOHOL;

BIOCOMPATIBILITY; BIODEGRADABILITY; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; ENDOCYTOSIS; ENTERAL DRUG ADMINISTRATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PHARMACEUTICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PLASMA HALF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

INTRAVENOUS ROUTE; OCULAR ADMINISTRATION; ORAL ROUTE; POLYMER-DRUG CONJUGATES; PULMONARY ADMINISTRATION; ROUTES OF ADMINISTRATION; TRANSDERMAL ROUTE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84903161886     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.912779     Document Type: Review

References (70)

1. Haag R, Kratz F. Polymer therapeutics: Concepts and applications. Angew Chem Int Ed 2006;45:1198-215 (Pubitemid 44097641
2. Jatzkewitz H. Peptamin (glycyl-L-leucylmescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z Naturforsch 1955;10b:2731
3. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60 (Pubitemid 37361705
4. Regelson W. Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy. J Bioact Compat Polym 1986;1:84-106
5. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975;51:135-53
6. Maeda H, Wu J, Matsumura Y, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-84 (Pubitemid 30122932
7. Gaspar R, Duncan R. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Del Rev 2009;61:1220-31
8. Zempsky WT. Alternative routes of drug administration-Advantages and disadvantages (subject review). Pediatrics 1998;101:730-1 (Pubitemid 28180171
9. Veronese FM. PEGylated protein Drugs: Basic science and clinical applications. Birkhäuser Verlag, Basel; 2009
10. Kopecek J, Kopecková P. Design of polymer-drug conjugates. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim; 2012
11. Markovsky E, Baabur-Cohen H, Eldar-Boock A, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012;161:446-60
12. Pasut G, Veronese F. Polymer-drug conjugation, recent achievements and general strategies. Prog Poly Sci 2007;32:933-61 (Pubitemid 47198290
13. Kopecek J. Polymer-drug conjugates: Origins, progress to date and future directions. Adv Drug Del Rev 2013;65:49-59
14. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2009;6:688-701 (Pubitemid 44286001
15. Jain RK. Barriers to drug-delivery in solid tumors. Sci Am 1994;271:58-65
16. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-An obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13 (Pubitemid 39331152
17. Seymour LW, Duncan R, Strohalm J, et al. Effect of molecular weight (MW) of N-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J Biomed Mat Res 1987;21:1341-58
18. Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995;84:349-54
19. Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1-16
20. Pang X, Du HL, Zhang HQ, et al. Polymer-drug conjugates: Present state of play and future perspectives. Drug Discov Today 2013;18:1316-22
21. Duncan R, Richardson SCW. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: Opportunities and challenges in preparation. Mol Pharm 2012;9:2380-402
22. Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: The end of the beginning. Adv Drug Deliv Rev 2013;65:60-70
23. Vercauteren R, Bruneel D, Schacht E, et al. Effect of the chemical modification of dextran on the degradation by dextranases. J Bioact Compat Polym 1990;5:4-15 (Pubitemid 20150979
24. Danhauser-Ried S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOXOXD) Invest New Drugs 1993;11:187-95 (Pubitemid 23277239
25. Soepenberg O, de Jonge MJ, Sparreboom A, et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 2005;11:703-11 (Pubitemid 40116898
26. Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery Int J Pharm 1988;87:787-96
27. Terwogt JM, Schellens JH, Huinink WW, et al. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 1999;25:83-101 (Pubitemid 29353668
28. Kruijtzer C, Beijnen J, Schellens J Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: An overview. Oncologist 2002;7:516-30 (Pubitemid 36009000
29. Weinberger S, Martinez J. Characterization of hydrolysis of [leu] enkephalin and D-Ala2-[L-leu] enkephalin in rat plasma. J Pharmacol Exp Ther 1988;247:129-35
30. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs I: General considerations. Drug Discov Today 2013;18:25-34
31. Thanki K, Gangwal RP, Sangamwar AT, et al. Oral delicery of anticancer drugs: Challenges and opportunities. J Control Release 2013;170:15-40
32. Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013;154:1542-50
33. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: The glucose stabilization effects of HIM2. Diabetes Technol Ther 2002;4:459-66
34. Youn YS, Jung JY, Oh SH, et al Improved intestinal delivery of salmon calcitonin by Lys18-Amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 2006;114:334-42 (Pubitemid 44310815
35. Nojima Y, Suzuki Y, Iguchi K, et al. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug Chem 2008;19:2253-9
36. Anwar M, Warsi MH, Mallick N, et al. Enhanced bioavailability of nano-sized chitosan-Atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci 2011;44:241-9
37. Lee E, Kim H, Lee IH, et al In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009;140:79-85
38. Lee E, Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51:6442-9
39. Lee E, Lee J, Jon S. A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan. Bioconjug Chem 2010;21:1720-3
40. Sakthivel T, Toth I, Florence AT. Distribution of a lipidic 2.5 nm diameter dendrimer carrier after oral administration Int J Pharm 1999;183:51-5 (Pubitemid 29248828
41. Wiwattanapatapee R, Carreno-Gomez B, Malik N, et al. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system?. Pharm Res 2000;17:991-8
42. Lin Y, Fujimori T, Kawaguchi N, et al. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J Control Release 2011;149:21-8
43. Mignani S, Kazzouli SE, Bousmina M, et al. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview. Adv Drug Deliv Rev 2013;65:1316-30
44. Subedi RK, Oh SY, Chun MK, et al. Recent advances in transdermal drug delivery. Arch Pharm Res 2010;33:339-51
45. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3:115-24 (Pubitemid 38239773
46. Karande P, Jain A, Ergun K, et al. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc Natl Acad Sci USA 2005;102:4688-93 (Pubitemid 40471515
47. Finnin BC, Morgan TM. Transdermal penetration enhancers: Applications, limitations, and potential. J Pharm Sci 1999;88:955-8 (Pubitemid 29480582
48. Sharma K, Singh V, Arora A. Natural biodegradable polymers as matrices in transdermal drug delivery Int J Drug Dev Res 2011;3:85-103
49. Yang Y, Bugno J, Hong S. Nanoscale polymeric penetration enhancers in topical drug delivery. Polym Chem 2013;4:2651-7
50. Filipowicz A, Wolowiec S. Bioconjugates of PAMAM dendrimers with transretinal, pyridoxal, and pyridoxal phosphate Int J Nanomed 2012;7:4819-28
51. Venuganti VV, Perumal OP. Poly (amidoamine) dendrimers as skin penetration enhancers: Influence of charge, generation, and concentration. J Pharm Sci 2008;98:2345-56
52. Yang Y, Sunoqrot S, Stowell C, et al. The effect of size, surface charge and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromelecules 2012;13:2154-62
53. Oh EJ, Park K, Kim KS, et al. Target specific and long-Acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010;141:2-12
54. Yang JA, Kim ES, Kwon JH, et al. Transdermal delivery of hyaluronic acidhuman growth hormone conjugate. Biomaterials 2012;33:5947-54
55. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70 (Pubitemid 350138179
56. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery Int J Nanomed 2009;4:299-319
57. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-44
58. Xie Y, Aillon KL, Cai S, et al. Pulmonary delivery of cisplatinhyaluronan conjugates via endotracheal instillation for the treatment of lung cancer Int J Pharm 2010;392:156-63
59. Inapagolla R, Guru BR, Kurtoglu YE, et al In vivo efficacy of dendrimermethylprednisolone conjugate formation for the treatment of lung inflammation Int J Pharm 2010;339:140-7
60. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I. Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99 (Pubitemid 37491710
61. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3-36 (Pubitemid 26167852
62. Carvalho TC, Peters JI, Williams RO III Influence of particle size on regional lung deposition - what evidence is there? Int J Pharm 2011;406:1-10
63. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99 (Pubitemid 37491710
64. Weiner AL, Gilger BC. Advancements in ocular drug delivery. Vet Ophthalmol 2010;13:395-406
65. Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res 2009;26:1197-216
66. Spataro G, Malecaze F, Turrin CO, et al. Designing dendrimers for ocular drug delivery. Eur J Med Chem 2010;45:326-34
67. Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012;33:979-88
68. Shaunak S, Thomas S, Gianasi E, et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004;22:977-84 (Pubitemid 39014474
69. Kyyr€onen K, Hume L, Benedetti L, et al. Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: In vitro and in vivo release studies Int J Pharm 1992;80:161-9
70. Oh EJ, Choi JS, Kim H, et al. Anti-Flt1 peptide-Hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials 2011;32:3115-23